MetLife Investment Management’s Phathom Pharmaceuticals PHAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $248K | Buy |
25,845
+1,479
| +6% | +$14.2K | ﹤0.01% | 2075 |
|
|
2025
Q1 | $153K | Hold |
24,366
| – | – | ﹤0.01% | 2330 |
|
|
2024
Q4 | $198K | Buy |
24,366
+5,337
| +28% | +$43.3K | ﹤0.01% | 2312 |
|
|
2024
Q3 | $344K | Buy |
19,029
+740
| +4% | +$13.4K | ﹤0.01% | 1982 |
|
|
2024
Q2 | $188K | Buy |
18,289
+1,818
| +11% | +$18.7K | ﹤0.01% | 2282 |
|
|
2024
Q1 | $175K | Hold |
16,471
| – | – | ﹤0.01% | 2266 |
|
|
2023
Q4 | $150K | Hold |
16,471
| – | – | ﹤0.01% | 2393 |
|
|
2023
Q3 | $171K | Buy |
16,471
+4,169
| +34% | +$43.2K | ﹤0.01% | 2296 |
|
|
2023
Q2 | $176K | Hold |
12,302
| – | – | ﹤0.01% | 2356 |
|
|
2023
Q1 | $87.8K | Hold |
12,302
| – | – | ﹤0.01% | 2601 |
|
|
2022
Q4 | $138K | Hold |
12,302
| – | – | ﹤0.01% | 2452 |
|
|
2022
Q3 | $136K | Hold |
12,302
| – | – | ﹤0.01% | 2520 |
|
|
2022
Q2 | $104K | Hold |
12,302
| – | – | ﹤0.01% | 2699 |
|
|
2022
Q1 | $167K | Buy |
12,302
+4,540
| +58% | +$61.8K | ﹤0.01% | 2462 |
|
|
2021
Q4 | $153K | Hold |
7,762
| – | – | ﹤0.01% | 2219 |
|
|
2021
Q3 | $249K | Hold |
7,762
| – | – | ﹤0.01% | 1947 |
|
|
2021
Q2 | $263K | Buy |
7,762
+2,674
| +53% | +$90.5K | ﹤0.01% | 1981 |
|
|
2021
Q1 | $191K | Hold |
5,088
| – | – | ﹤0.01% | 2077 |
|
|
2020
Q4 | $169K | Hold |
5,088
| – | – | ﹤0.01% | 2070 |
|
|
2020
Q3 | $187K | Hold |
5,088
| – | – | ﹤0.01% | 1903 |
|
|
2020
Q2 | $167K | Hold |
5,088
| – | – | ﹤0.01% | 2003 |
|
|
2020
Q1 | $131K | Buy |
+5,088
| New | +$131K | ﹤0.01% | 1931 |
|